Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus

PHASE3RecruitingINTERVENTIONAL
Enrollment

406

Participants

Timeline

Start Date

June 23, 2023

Primary Completion Date

September 23, 2025

Study Completion Date

September 23, 2026

Conditions
Catheter BacteremiaStaphylococcus Aureus Infection
Interventions
DRUG

Dalbavancin administration

"A single-dose of intraveneuse (IV) administration of dalbavancin of 1500 mg.~In case of patients with chronic renal impairment (creatinin clairance \< 30mL/min), a single-dose of IV administration of reduced dalbavancin of 1000 mg."

DRUG

Standard antibiotic therapy

Standard Antibiotic therapy according to national recommendations. During the study, the start of treatment is considered to be the day of inclusion/randomization (even if active antiobiotic treatment was started, less than 72 hours ago according to inclusion criteria).

Trial Locations (2)

24019

RECRUITING

Infectious Diseases Department, CH PERIGUEUX, Périgueux

92380

NOT_YET_RECRUITING

Infectious Diseases Department, Raymond-Poincaré Hospital - APHP, Garches

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Centre Hospitalier de Perigueux

OTHER

collaborator

Advanz Pharma

INDUSTRY

collaborator

Nantes University Hospital

OTHER

collaborator

Centre National de Référence des staphylocoques

UNKNOWN

lead

Assistance Publique - Hôpitaux de Paris

OTHER